Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Price Target at $9.00

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has earned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $9.40.

AMRX has been the topic of a number of analyst reports. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a research note on Friday, September 6th. Barclays increased their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Finally, Truist Financial boosted their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd.

Amneal Pharmaceuticals Stock Down 2.2 %

AMRX stock opened at $8.46 on Tuesday. The company’s 50 day moving average price is $8.16 and its 200 day moving average price is $7.08. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of -15.11 and a beta of 1.18. Amneal Pharmaceuticals has a fifty-two week low of $3.36 and a fifty-two week high of $8.94. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.82 and a current ratio of 1.33.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Friday, August 9th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. Amneal Pharmaceuticals had a negative net margin of 6.72% and a positive return on equity of 1,235.03%. The company had revenue of $701.78 million for the quarter, compared to the consensus estimate of $657.43 million. On average, equities research analysts anticipate that Amneal Pharmaceuticals will post 0.52 EPS for the current fiscal year.

Institutional Trading of Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rothschild Investment LLC purchased a new position in Amneal Pharmaceuticals during the 2nd quarter worth approximately $26,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at approximately $42,000. Atlanta Consulting Group Advisors LLC purchased a new position in shares of Amneal Pharmaceuticals during the first quarter worth approximately $61,000. nVerses Capital LLC acquired a new position in shares of Amneal Pharmaceuticals in the 2nd quarter valued at $62,000. Finally, Trexquant Investment LP purchased a new stake in Amneal Pharmaceuticals in the 4th quarter valued at $65,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.